No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3

M. Wiese; F. Schill; D. Sturm; S. Pfister; E. Hulleman; S. A. Johnsen; C. M. Kramm

doi:10.1055/s-0042-105292

No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3

M. Wiese, F. Schill, D. Sturm, S. Pfister, E. Hulleman, S. A. Johnsen, C. M. Kramm

Pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	113-117
Journal	Klinische Pädiatrie
Volume	228
Issue number	3
DOIs	https://doi.org/10.1055/s-0042-105292
Publication status	Published - May 2016

Access to Document

10.1055/s-0042-105292

Cite this

@article{01533f8081954042a099d15bc691559b,

title = "No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3",

keywords = "EZH2 inhibition, Tazemetostat (EPZ-6438), cancer epigenetics, histone 3 mutation, pediatric high-grade glioma (pedHGG)",

author = "M. Wiese and F. Schill and D. Sturm and S. Pfister and E. Hulleman and Johnsen, {S. A.} and Kramm, {C. M.}",

year = "2016",

month = may,

doi = "10.1055/s-0042-105292",

language = "English",

volume = "228",

pages = "113--117",

journal = "Klinische P{\"a}diatrie",

issn = "0300-8630",

publisher = "Georg Thieme Verlag",

number = "3",

}

No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3. / Wiese, M.; Schill, F.; Sturm, D.; Pfister, S.; Hulleman, E.; Johnsen, S. A.; Kramm, C. M.

In: Klinische Pädiatrie, Vol. 228, No. 3, 05.2016, p. 113-117.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3

AU - Wiese, M.

AU - Schill, F.

AU - Sturm, D.

AU - Pfister, S.

AU - Hulleman, E.

AU - Johnsen, S. A.

AU - Kramm, C. M.

PY - 2016/5

Y1 - 2016/5

KW - EZH2 inhibition

KW - Tazemetostat (EPZ-6438)

KW - cancer epigenetics

KW - histone 3 mutation

KW - pediatric high-grade glioma (pedHGG)

U2 - 10.1055/s-0042-105292

DO - 10.1055/s-0042-105292

M3 - Article

C2 - 27135271

VL - 228

SP - 113

EP - 117

JO - Klinische Pädiatrie

JF - Klinische Pädiatrie

SN - 0300-8630

IS - 3

ER -